(UroToday.com) In an oral presentation in the Refining the Treatment of Bladder Cancer session at the 12th European Multidisciplinary Congress on Urological Cancers (EMUC), Dr. Marc-Oliver Grimm presented an update on treatment options for patients with high-risk non-muscle-invasive bladder cancer. He began by emphasizing that this disease state is characterized by a high risk of recurrence and progression. For the past many decades, the standard of care for these patients has been intravesical Bacillus Calmette Guerin (BCG) though there are shortages of this treatment.